000			a
999			_c20241 _d20241
003			OSt
005			20231205101339.0
008			231205b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_912835 _aVashi, Dhara
245			_aDevelopment and validation of uv spectroscopic method for simultaneous estimation of remogliflozin etabonate and vildagliptin in bulk and pharmaceutical dosage form
250			_aVol.13(2), Apr-Jun
260			_aRaipur _bAsian Pharma Press _c2023
300			_a69-73p.
520			_aA new, simple, precise, accurate, reproducible, and efficient UV spectroscopic method was developed and validated for simultaneous estimation of Remogliflozin Etabonate and Vildagliptin in pure and pharmaceutical dosage form. The ??max of Remogliflozin Etabonate and Vildagliptin in Methanol were found to be 236nm and 215nm, respectively. Calibration curves of Remogliflozin Etabonate and Vildagliptin were found to be linear in the concentration ranges of 5-25µg/mL and 1-5µg/mL with their correlation coefficient values (R2) 0.9993 and 0.9998, respectively. LOD and LOQ were found to be 0.0246µg/mL and 0.0745µg/mL for Remogliflozin Etabonate and 0.0278µg/mL and 0.0842µg/mL for Vildagliptin, respectively. In the precision study, the % RSD value was found within limits (RSD < 2%). The percentage recovery at various concentration levels varied from 99.25 to 101.06% for Remogliflozin Etabonate and 99.58 to 100.41% for Vildagliptin, respectively. The proposed method can be applied successfully for the simultaneous estimation of Remogliflozin Etabonate and Vildagliptin in pure and pharmaceutical dosage form. In this method simultaneous equation method was applied to find assay of both drugs in pharmaceutical dosage form.
650		0	_94639 _aPHARMACEUTICS
700			_922296 _aChaudhari, Hetvi
773	0		_x2231-5667 _dRaipur A & V Publications _tAsian journal of pharmaceutical analysis
856			_uhttps://ajpaonline.com/AbstractView.aspx?PID=2023-13-2-1 _yClick here
942			_2ddc _cAR